The 2012 Briganti nomogram not only predicts lymph node involvement but also disease progression in surgically treated intermediate-risk prostate cancer patients with PSA <10 ng/mL, ISUP grade group 3, and clinical stage up to cT2b.

IF 3.1 3区 医学 Q1 UROLOGY & NEPHROLOGY International Braz J Urol Pub Date : 2024-07-01 DOI:10.1590/S1677-5538.IBJU.2024.0003
Antonio Benito Porcaro, Andrea Panunzio, Rossella Orlando, Francesca Montanaro, Alberto Baielli, Francesco Artoni, Sebastian Gallina, Alberto Bianchi, Giovanni Mazzucato, Emanuele Serafin, Giulia Marafioti Patuzzo, Alessandro Veccia, Riccardo Rizzetto, Matteo Brunelli, Filippo Migliorini, Riccardo Bertolo, Alessandro Tafuri, Maria Angela Cerruto, Alessandro Antonelli
{"title":"The 2012 Briganti nomogram not only predicts lymph node involvement but also disease progression in surgically treated intermediate-risk prostate cancer patients with PSA <10 ng/mL, ISUP grade group 3, and clinical stage up to cT2b.","authors":"Antonio Benito Porcaro, Andrea Panunzio, Rossella Orlando, Francesca Montanaro, Alberto Baielli, Francesco Artoni, Sebastian Gallina, Alberto Bianchi, Giovanni Mazzucato, Emanuele Serafin, Giulia Marafioti Patuzzo, Alessandro Veccia, Riccardo Rizzetto, Matteo Brunelli, Filippo Migliorini, Riccardo Bertolo, Alessandro Tafuri, Maria Angela Cerruto, Alessandro Antonelli","doi":"10.1590/S1677-5538.IBJU.2024.0003","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>We assessed the prognostic impact of the 2012 Briganti nomogram on prostate cancer (PCa) progression in intermediate-risk (IR) patients presenting with PSA <10ng/mL, ISUP grade group 3, and clinical stage up to cT2b treated with robot assisted radical prostatectomy eventually associated with extended pelvic lymph node dissection.</p><p><strong>Materials and methods: </strong>From January 2013 to December 2021, data of surgically treated IR PCa patients were retrospectively evaluated. Only patients presenting with the above-mentioned features were considered. The 2012 Briganti nomogram was assessed either as a continuous and a categorical variable (up to the median, which was detected as 6%, vs. above the median). The association with PCa progression, defined as biochemical recurrence, and/or metastatic progression, was evaluated by Cox proportional hazard regression models.</p><p><strong>Results: </strong>Overall, 147 patients were included. Compared to subjects with a nomogram score up to 6%, those presenting with a score above 6% were more likely to be younger, had larger/palpable tumors, presented with higher PSA, underwent tumor upgrading, harbored non-organ confined disease, and had positive surgical margins at final pathology. PCa progression, which occurred in 32 (21.7%) cases, was independently predicted by the 2012 Briganti nomogram both considered as a continuous (Hazard Ratio [HR]:1.04, 95% Confidence Interval [CI]:1.01-1.08;p=0.021), and a categorical variable (HR:2.32; 95%CI:1.11-4.87;p=0.026), even after adjustment for tumor upgrading.</p><p><strong>Conclusions: </strong>In IR PCa patients with PSA <10ng/mL, ISUP grade group 3, and clinical stage up to cT2b, the 2012 Briganti nomogram independently predicts PCa progression. In this challenging subset of patients, this tool can identify prognostic subgroups, independently by upgrading issues.</p>","PeriodicalId":49283,"journal":{"name":"International Braz J Urol","volume":null,"pages":null},"PeriodicalIF":3.1000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11262719/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Braz J Urol","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1590/S1677-5538.IBJU.2024.0003","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: We assessed the prognostic impact of the 2012 Briganti nomogram on prostate cancer (PCa) progression in intermediate-risk (IR) patients presenting with PSA <10ng/mL, ISUP grade group 3, and clinical stage up to cT2b treated with robot assisted radical prostatectomy eventually associated with extended pelvic lymph node dissection.

Materials and methods: From January 2013 to December 2021, data of surgically treated IR PCa patients were retrospectively evaluated. Only patients presenting with the above-mentioned features were considered. The 2012 Briganti nomogram was assessed either as a continuous and a categorical variable (up to the median, which was detected as 6%, vs. above the median). The association with PCa progression, defined as biochemical recurrence, and/or metastatic progression, was evaluated by Cox proportional hazard regression models.

Results: Overall, 147 patients were included. Compared to subjects with a nomogram score up to 6%, those presenting with a score above 6% were more likely to be younger, had larger/palpable tumors, presented with higher PSA, underwent tumor upgrading, harbored non-organ confined disease, and had positive surgical margins at final pathology. PCa progression, which occurred in 32 (21.7%) cases, was independently predicted by the 2012 Briganti nomogram both considered as a continuous (Hazard Ratio [HR]:1.04, 95% Confidence Interval [CI]:1.01-1.08;p=0.021), and a categorical variable (HR:2.32; 95%CI:1.11-4.87;p=0.026), even after adjustment for tumor upgrading.

Conclusions: In IR PCa patients with PSA <10ng/mL, ISUP grade group 3, and clinical stage up to cT2b, the 2012 Briganti nomogram independently predicts PCa progression. In this challenging subset of patients, this tool can identify prognostic subgroups, independently by upgrading issues.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
2012 年布里甘蒂提名图不仅能预测淋巴结受累情况,还能预测接受过手术治疗的 PSA <10 纳克/毫升、ISUP 等级 3 组和临床分期达 cT2b 的中危前列腺癌患者的疾病进展情况。
目的:我们评估了 2012 年 Briganti 提名图对出现 PSA 的中危(IR)前列腺癌(PCa)进展的预后影响:回顾性评估了2013年1月至2021年12月期间接受手术治疗的IR PCa患者的数据。仅考虑具有上述特征的患者。2012 年布里甘蒂提名图作为连续变量和分类变量进行了评估(中位数以下检测为 6%,中位数以上检测为 6%)。Cox比例危险回归模型评估了与PCa进展(定义为生化复发和/或转移性进展)之间的关系:结果:共纳入 147 名患者。与提名图评分不超过6%的受试者相比,评分超过6%的受试者更可能更年轻、肿瘤更大/可触及、PSA更高、接受过肿瘤升级、患有非器官局限性疾病、最终病理检查时手术切缘呈阳性。32例(21.7%)PCa患者的病情恶化可由2012年Briganti提名图独立预测,无论是连续变量(危险比[HR]:1.04,95%置信区间[CI]:1.01-1.08;p=0.021)还是分类变量(HR:2.32;95%CI:1.11-4.87;p=0.026),即使在对肿瘤升级进行调整后也是如此:结论:在PSA
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
International Braz J Urol
International Braz J Urol UROLOGY & NEPHROLOGY-
CiteScore
4.60
自引率
21.60%
发文量
246
审稿时长
6-12 weeks
期刊介绍: Information not localized
期刊最新文献
Development of nerves and vessels in the penis during the human fetal period. Evidence of restorative therapies in the treatment of Peyronie disease: A narrative review. Robot-assisted radical nephroureterectomy using the KangDuo Surgical Robot-01 System versus the da Vinci System: a multicenter prospective randomized controlled trial. Safety and efficacy of vacuum-assisted mini-percutaneous nephrolithotomy for the treatment of renal stone disease: an analysis of stone free status and postoperative infectious complications. Single Port Robotic Nephrectomy via lower anterior retroperitoneal approach: feasible, safe and effective option in surgically complex patients.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1